Author

E.S. Barnett

Observed names: E. Barnett, Evan Barnett

Observed institutions: Memorial Sloan Kettering Cancer Center, St Mary's Hospital, Idaho College of Osteopathic Medicine

OpenAlex ID: A5113345409

Effect of Potent Topical Steroids on Plasma-cortisol Levels of Infants and Children With Eczema

1969 · Michael Feiwel, V.H.T. James, et al. · The Lancet · 78

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

2021 · H.I. Scher, A.J. Armstrong, et al. · European Journal of Cancer · 54

243eP Evaluation of a host immune classifier proteomic signature in microsatellite-instability high or mismatch-repair deficient solid tumors treated with pembrolizumab

2025 · E.S. Barnett, T.T. Erazo, et al. · Annals of Oncology

Psycho-oncology

2024 · Daniel C. McFarland, Harsimar Kaur, et al. · Elsevier eBooks

613P Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)

2021 · N.M. Keegan, J. Schonhoft, et al. · Annals of Oncology

Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes

2017 · H. Scher, R.P. Graf, et al. · Annals of Oncology

Works count: 6

Citation count: 132

H-index: 2

I10-index: 2